RxDoctor Payments Data

Ricardo Zamora, MD

General Practice · Tamarac, FLNPI 1326291964

Payments from drug & device makers

$3,154in general payments, 2019–2025

Across 101 payments — averaging $31.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Musculoskeletal Transplant Foundation Inc.$1K
  • Novo Nordisk$529
  • Pfizer$239
  • Johnson & Johnson$219
  • Amarin Pharma, Inc.$195
  • Lilly USA, LLC$184
  • plus $689 from 13 others

What the payments were for

  • Food & beverage$3,154100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,154 in reported general payments places this provider in the 90th percentile of 6,901 general practice providers in Florida.

See all general practice providers in Florida

Medicare billing

Part B allowed, 2024
$7,306
Medicare patients
23
Services billed
72

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin73$126,009
EliquisApixaban53$82,870
VascepaIcosapent Ethyl88$74,866
JanuviaSitagliptin Phosphate36$53,427
OzempicSemaglutide39$46,113
RybelsusSemaglutide20$43,357
FarxigaDapagliflozin Propanediol26$42,760
XareltoRivaroxaban30$40,655
JanumetSitagliptin Phos/Metformin Hcl21$34,468
MounjaroTirzepatide21$21,855
LinzessLinaclotide21$21,455
MyrbetriqMirabegron15$15,795
BrilintaTicagrelor14$15,358
LumiganBimatoprost26$14,001
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$11,409

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$36$126,00973 claims
Novo NordiskOzempic, Rybelsus$529$89,47059 claims
PfizerEliquis$239$82,87053 claims
AstraZenecaFarxiga, Brilinta$118$58,11840 claims
Johnson & JohnsonXarelto$219$40,65530 claims
Lilly USA, LLCMounjaro$184$21,85521 claims
GSKTrelegy Ellipta$13$11,40914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,901 general practice providers in Florida.

Other general practice in Tamarac

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →